Literature DB >> 17308294

Reversible limbic encephalitis with antibodies against the membranes of neurones of the hippocampus.

H Shimazaki, Y Ando, I Nakano, J Dalmau.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17308294      PMCID： PMC2117656          DOI： 10.1136/jnnp.2006.104513

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  5 in total

1.  A new cause of limbic encephalopathy.

Authors:  Robert B Darnell; Jerome B Posner
Journal:  Brain       Date:  2005-08       Impact factor: 13.501

2.  EFA6A-like antibodies in paraneoplastic encephalitis associated with immature ovarian teratoma: a case report.

Authors:  Reiji Koide; Toshio Shimizu; Kazunori Koike; Josep Dalmau
Journal:  J Neurooncol       Date:  2006-06-29       Impact factor: 4.130

3.  Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma.

Authors:  Roberta Vitaliani; Warren Mason; Beau Ances; Theodore Zwerdling; Zhilong Jiang; Josep Dalmau
Journal:  Ann Neurol       Date:  2005-10       Impact factor: 10.422

4.  Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients.

Authors:  S H Gultekin; M R Rosenfeld; R Voltz; J Eichen; J B Posner; J Dalmau
Journal:  Brain       Date:  2000-07       Impact factor: 13.501

5.  Recommended diagnostic criteria for paraneoplastic neurological syndromes.

Authors:  F Graus; J Y Delattre; J C Antoine; J Dalmau; B Giometto; W Grisold; J Honnorat; P Sillevis Smitt; Ch Vedeler; J J G M Verschuuren; A Vincent; R Voltz
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-08       Impact factor: 10.154
  5 in total
  12 in total

Review 1.  [Anti-NMDA-receptor encephalitis. An interdisciplinary clinical picture].

Authors:  H Prüss; J Dalmau; V Arolt; K-P Wandinger
Journal:  Nervenarzt       Date:  2010-04       Impact factor: 1.214

Review 2.  Paraneoplastic syndromes of the CNS.

Authors:  Josep Dalmau; Myrna R Rosenfeld
Journal:  Lancet Neurol       Date:  2008-04       Impact factor: 44.182

3.  Update on paraneoplastic neurologic disorders.

Authors:  Myrna R Rosenfeld; Josep Dalmau
Journal:  Oncologist       Date:  2010-05-17

Review 4.  Paraneoplastic syndromes: an approach to diagnosis and treatment.

Authors:  Lorraine C Pelosof; David E Gerber
Journal:  Mayo Clin Proc       Date:  2010-09       Impact factor: 7.616

5.  A patient with encephalitis associated with NMDA receptor antibodies.

Authors:  Lauren H Sansing; Erdem Tüzün; Melissa W Ko; Jennifer Baccon; David R Lynch; Josep Dalmau
Journal:  Nat Clin Pract Neurol       Date:  2007-05

6.  Neurological response to early removal of ovarian teratoma in anti-NMDAR encephalitis.

Authors:  M Seki; S Suzuki; T Iizuka; T Shimizu; Y Nihei; N Suzuki; J Dalmau
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-11-21       Impact factor: 10.154

7.  Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents.

Authors:  Nicole R Florance; Rebecca L Davis; Christopher Lam; Christina Szperka; Lei Zhou; Saba Ahmad; Cynthia J Campen; Heather Moss; Nadja Peter; Amy J Gleichman; Carol A Glaser; David R Lynch; Myrna R Rosenfeld; Josep Dalmau
Journal:  Ann Neurol       Date:  2009-07       Impact factor: 10.422

8.  Autoimmune channelopathies of the nervous system.

Authors:  Kleopas A Kleopa
Journal:  Curr Neuropharmacol       Date:  2011-09       Impact factor: 7.363

9.  PET/CT in the evaluation of anti-NMDA-receptor encephalitis: What we need to know as a NM physician.

Authors:  S Padma; P Shanmuga Sundaram; Bobby Varkey Marmattom
Journal:  Indian J Nucl Med       Date:  2011-04

10.  Profiling neuronal ion channelopathies with non-invasive brain imaging and dynamic causal models: Case studies of single gene mutations.

Authors:  Jessica R Gilbert; Mkael Symmonds; Michael G Hanna; Raymond J Dolan; Karl J Friston; Rosalyn J Moran
Journal:  Neuroimage       Date:  2015-09-03       Impact factor: 6.556
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.